SCHEMBL13859348

SCHEMBL13859348

N#C/C(=C/C1CC1)C(=O)Nc1cccc(Nc2nccc(-c3ccccc3)n2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 11/20 0.52
▸ BCR P11274 11/20 0.52
▸ SRC P12931 6/20 0.52
▸ PDGFRB P09619 6/20 0.52
▸ PDGFRA P16234 6/20 0.52
▸ PRKCA P17252 5/20 0.52
▸ PRKCD Q05655 3/20 0.52
▸ PRKD3 O94806 1/20 0.52
▸ PRKCG P05129 1/20 0.52
▸ PRKCB P05771 1/20 0.52
▸ PRKCH P24723 1/20 0.52
▸ PRKCI P41743 1/20 0.52
▸ PRKCE Q02156 1/20 0.52
▸ PRKCQ Q04759 1/20 0.52
▸ PRKCZ Q05513 1/20 0.52
▸ PRKD1 Q15139 1/20 0.52
▸ MAPK8 P45983 2/20 0.51
▸ PIK3CG P48736 2/20 0.51
▸ GSK3B P49841 2/20 0.51
▸ CAMKK2 Q96RR4 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13859349 1.00 ABL1 (0.52) ABL1BCRSRCPDGFRBPDGFRA
SCHEMBL13859526 0.88 AURKA (0.50) ABL1SRCPRKCDPRKD3PRKCG
SCHEMBL13859528 0.88 AURKA (0.50) ABL1SRCPRKCDPRKD3PRKCG
SCHEMBL13859535 0.85 EGFR (0.47) JAK3
SCHEMBL13859536 0.85 EGFR (0.47) JAK3
SCHEMBL13859384 0.85 PLK4 (0.44) ABL1BCRSRCPDGFRBPDGFRA
SCHEMBL13859385 0.85 PLK4 (0.44) ABL1BCRSRCPDGFRBPDGFRA
SCHEMBL13859351 0.85 PRKCA (0.57) ABL1BCRPDGFRBPDGFRAPRKCA
SCHEMBL13859353 0.85 PRKCA (0.57) ABL1BCRPDGFRBPDGFRAPRKCA
SCHEMBL13859563 0.83 JAK3 (0.49) JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9580427-B2 Kinase inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-02-28 — — US disclosed
US-20140323464-A1 KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-10-30 — — US disclosed
EP-2710007-A2 KINASE INHIBITORS The Regents of the University of California (US) 2014-03-26 — — EP disclosed
WO-2012158843-A2 KINASE INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-11-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323464-A1 KINASE INHIBITORS MAP3K20, MAP3K19, MAP3K1 ABL1 23/4885BCR 649/4885SRC 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback